Cladribine has been reported to have little activity in fludarabinerefractory chronic lymphocytic leukemia (CLL). We sought to determine whether resistance to therapy with cladribine in fludarabine-refractory CLL patients represented primary drug resistance or the inability to tolerate the myelosuppression associated with this therapy. Patients with fludarabine refractory CLL patients without severe thrombocytopenia (platelets Ն50 × 10 9 /l) or granulocytopenia (neutrophils Ͼ1.5 × 10 9 /l) were enrolled. All patients received cladribine (0.14 mg/kg) as a 2-h intravenous infusion daily for 5 days, repeated every 4 weeks. Patients received up to six cycles of therapy. Twenty-eight patients enrolled; 13 had intermediate (Rai stage I or II) and 15 high (Rai stage III and IV) risk stages. No patient had a complete remission, but nine (32%; 95% confidence interval, 15-49%) attained a partial remission when assessed using the modified NCI criteria (1996). The median time to relapse for responders was 12 months, while median progression-free survival for the entire group was 9 months (95% confidence interval, 4-14 months). The median overall survival was 2.2 years (95% confidence interval, 0.8-3.1 years). Response was predicted by pre-treatment Rai status with seven of 13 (54%) intermediate risk vs two of 15 (13%) high-risk patients responding (P = 0.04). Toxicity was myelosuppression and infections (grade 3-5: neutropenia 75%, thrombocytopenia 68%, and infections 43%). Cladribine has modest clinical activity and considerable toxicity in a very selected group of patients with fludarabine-refractory CLL lacking pre-treatment neutropenia and thrombocytopenia.
Introduction
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia occurring in the western hemisphere and accounts for 25% of all leukemias. Despite the greater than 10-year life expectancy in early stage patients, CLL remains an incurable illness. 1, 2 Until recently, therapy for CLL has mainly included oral alkylator therapy (chlorambucil or cyclophosphamide) with or without prednisone. Identification of the efficacy of fludarabine, 3, 4 cladribine [5] [6] [7] [8] and pentostatin [9] [10] [11] for alkylator-refractory CLL has altered the therapeutic approach utilized for many CLL patients. Indeed, the Food and Drug Administration approved fludarabine for use in alkylator resistant CLL in 1991. A promising phase II study 12 led to three prospective phase III trials of fludarabine in previously untreated CLL patients. Both superior response rates 13, 14 and progression-free survival [13] [14] [15] were observed with fludarabine compared to alkylator-based (cyclophosphamide, adriamycin, and prednisone or chlorambucil) therapies. These trials have However, treatment options for patients with fludarabinerefractory CLL are limited. A preliminary report that noted responses to cladribine in patients with fludarabine-refractory CLL prompted great interest. Fludarabine and cladribine are relatively similar structural analogs and cross-resistance would be expected. 16 Subsequent experience from several other groups failed to confirm these results and demonstrated considerable toxicity from cladribine due to myelosuppression and infections. [17] [18] [19] Because the majority of fludarabinerefractory patients have cytopenias and because cladribine can produce prolonged myelosuppression, a clinical trial was undertaken by the Cancer and Leukemia Group B (CALGB) to assess the efficacy and toxicity of cladribine in a subset of fludarabine refractory CLL patients without severe baseline cytopenias.
Methods

Subjects
Patients were enrolled on this multi-center trial performed by the CALGB after approval by local institutional review boards. All patients gave written informed consent. Patients were required to have histological documented CLL as defined by the modified National Cancer Institute guidelines 20 and to require therapy according to these same criteria. All patients had fludarabine previously and either had progression after a minimum of two cycles of fludarabine, stable disease after a minimum of four cycles, or relapse after attaining a partial response within 3 months of completing therapy. Patients could not have received more than six cycles of fludarabine or more than three prior therapies. Required clinical features included age older than 17 years, a CALGB performance status of less than or equal to 2, life expectancy of 12 weeks or greater, recovery from toxicity due to previous therapy for CLL, and absence of an active infection or prior autoimmune disease. Baseline hematological parameters required included platelets Ն50 × 10 9 /l) and granulocytes Ͼ1.5 × 10 9 /l. Laboratory requirements included a negative direct anti-globulin test. The serum creatinine, BUN, ALT, AST, and total bilirubin levels were less than or equal to 1.5 times the normal value. Patients with any other type of lymphoproliferative disorder or secondary malignancy were not eligible.
Pre-treatment evaluation
All patients underwent pre-treatment screening, which included a history, physical examination, laboratory and X-ray studies prior to entry on to the study. These tests included a complete blood count with differential (CBC), electrolytes, BUN, creatinine, total protein, albumin, calcium, phosphate, lactate dehydrogenase, uric acid, total bilirubin, ALT, AST, immunoglobulins, direct antiglobulin test, chest X-ray, bone marrow aspirate and biopsy, computerized tomography of the chest, abdomen, and pelvis, electrocardiogram, and urinalysis.
Treatment and dose modifications
All patients received cladribine 0.14 mg/kg per day administered as an intravenous infusion over 2 h daily for 5 consecutive days. This was repeated every 28 days provided there was recovery from hematological recovery of the absolute neutrophil count to Ͼ1.5 × 10 9 /l, and platelets to Ն75% of baseline value if these had dropped by Ͼ50% of baseline and the value was below 100 × 10 9 /l. Patients received a minimum of three cycles and maximum of six cycles of therapy. Prophylactic antibiotics and supportive care were administered at the discretion of the treating physician.
Assessment of toxicity and response
Hematological toxicity was graded according to the modified NCI criteria for CLL, 20 while non-hematological toxicity was graded according to the NCI Common Toxicity Criteria. Patients were assessed for disease response with a detailed clinical evaluation (physical examination with lymph node, liver, and spleen measurement; and CBC with differential 3 and 6 months after starting therapy). For patients attaining a clinical complete response, a bone marrow biopsy and aspirate was also performed at these times. Criteria for response utilized the revised NCI-sponsored Working Group Guidelines. 20 As specified by these guidelines, a response had to be maintained for a period of 2 months. Response duration was defined in responders from the time the response was first noted until progression or death (events) or last follow-up. Progression-free survival was defined similarly, except that follow-up began for all patients from the time of initiation of treatment. Survival time was measured from the time of initial treatment until time last seen alive (censored) or death (event).
Under the intention-to-treat principle, this report provides a summary of patient characteristics and outcome of therapy on all enrolled patients. Survival probabilities for response duration, progression-free survival and overall survival were estimated using the method of Kaplan-Meier. The standard errors for these estimates were obtained using the variance estimate of Peto. The association of response with pretreatment patient characteristics was tested with Fisher's exact test for dichotomous variables and with logistic regression's likelihood ratio test for numerical variables.
Results
Patient characteristics
Twenty-eight patients were enrolled on this protocol between 15 January 1993 and 18 December 1996. The pre-treatment features of these patients are summarized in Table 1 . The median age was 62 years (range, 30-87). The median number of prior treatments was 3 (range, 1-5). Only one patient received more than three treatments. All patients met the protocol criteria for having CLL that was refractory to fludarabine. Utilizing the modified Rai staging criteria, 15 (54%) of the patients were high risk.
Response to treatment and treatment outcome
All patients are evaluable for response and toxicity assessments. Utilizing an intent-to-treat analysis for all 28 patients enrolled on this trial, the overall response rate was 32% (95% confidence interval (CI) 15-49%). There were no complete responses. Of the nine patients with partial responses, only two (22%) had evidence of lymphadenopathy greater than 5 cm at presentation. Of note, the hematological status for these nine patients relative to Rai-modified risk factors improved (from high to intermediate) in only one patient (11%) and worsened in two (22%). The median response duration for the nine responding patients was 12 months (95% CI, 9-25) as depicted in Figure 1 . The median progression-
Figure 1
Response duration for responding patients (n = 9) with fludarabine-refractory chronic lymphocytic leukemia treated with cladribine on CALGB 9211.
Figure 2
Progression-free survival for all patients with fludarabinerefractory chronic lymphocytic leukemia (n = 28) treated with cladribine on CALGB 9211.
Figure 3
Overall survival for all patients with fludarabine-refractory chronic lymphocytic leukemia (n = 28) treated with cladribine on CALGB 9211. free survival for the entire group was 9 months (95% CI, 4-14) as depicted in Figure 2 . Twenty-five (89%) of the patients have died after a median survival of 26 months (95% CI, 10-37) as depicted in Figure 3 .
Toxicity
The toxicities observed during cladribine therapy are summarized in Table 2 . Despite the selection of a group of fludarabine- Table 2 Number (%) patients with toxicity during treatment Toxicity Gr 1 Gr 2 Gr 3 Gr 4 Gr 5 Neutropenia 1 (4) 1 (4) 3 (11) 18 (64) 0 (0) Thrombocytopenia2 (7) 7 ( (4) 4 (14) 21 (75) 1
(4) toxicity
Leukemia refractory CLL patients with modest fludarabine exposure and hematological impairment, toxicities were common: overall maximum grade 3 (14%), grade 4 (75%) or grade 5 (4%). Myelosuppression with grade 3 or 4 granulocytopenia (78%) and thrombocytopenia (68%) was frequently observed. Furthermore, grade 3-5 infections were noted in 43% of patients. These most commonly were bacterial infections, but opportunistic infections were also seen. Four patients had herpes simplex I/II (including one case involving the central nervous system), two had varicella zoster, and one each had CNS toxoplasmosis or candida esophagitis. Other extramedullary toxicity was uncommon during cladribine therapy.
Clinical and biologic features predicting response and toxicity to treatment
We performed univariate analyses of the pre-treatment features age, sex, pre-treatment lymphocyte count, anemia, thrombocytopenia, and risk group (Rai I/II was defined as low intermediate risk, Rai III/IV was defined as high risk) in an attempt to identify patients most likely to respond to cladribine. In this selected group of fludarabine-refractory patients, response was predicted only by pre-treatment Rai status with seven of 13 (54%) intermediate risk patients responding compared to only two of 15 (13%) high risk patients responding (P = 0.04).
Discussion
In this study we have observed that cladribine has modest clinical activity in patients with fludarabine-refractory CLL. Specifically, we measured a 32% partial response rate. No complete responses to cladribine therapy were noted. Among these responding patients, the median time to relapse was 12 months, while the median progression-free survival for the entire group of patients was 9 months. Toxicity of this regimen was substantial, with grade 3-5 granulocytopenia (75%), thrombocytopenia (68%) and infections (43%) being observed in a large proportion of both responding and non-responding patients. There was one treatment related death due to infection.
These clinical data and those previously reported by Julliuson and colleagues 16 demonstrating lack of clinical crossresistance between fludarabine and cladribine support the recent laboratory findings of potentially different mechanisms of cytotoxicity between fludarabine and cladribine. 21 Specifically, Genini and colleagues 21 have demonstrated that cladribine, but not fludarabine, induces apoptosis in human CLL cells through direct inhibition of mitochondrial function that is independent of caspase-9 activation. This contrasts with fludarabine where caspase 9-mediated apoptosis is critical to the cytotoxicity produced by this agent. 21 Thus, our clinical observations of absence of cross-resistance between cladribine and fludarabine are supported by in vitro laboratory studies in this same tumor cell type.
While our clinical findings do suggest lack of crossresistance between cladribine and fludarabine, both the generalizability and clinical significance of this observation at the present time are relatively limited. The patients included in this trial were highly selected for limited prior fludarabine therapy (no more than six cycles of prior treatment) and favorable hematological parameters that would likely predict for response to any given therapy. The selective nature of these eligibility requirements are best demonstrated by the long time required (approximately 4 years) to accrue 28 patients even within a large cooperative group. Despite these favorable characteristics, half of patients who were Rai stage I or II (intermediate risk) responded to therapy. In contrast, CLL patients with Rai stage III or IV (high risk) disease had only a 13% response rate. Indeed, the response rate observed in our study for this latter group of patients was similar to the 7% response rate reported by O'Brien and colleagues 19 in a 28 patient study that included more heavily pre-treated patients (median of four prior treatments). Furthermore, 82% of their patients were high risk by the modified Rai staging system. Similarly, grade 3-5 infectious toxicity was common in our study (43%) and in O'Brien's (65%), 19 emphasizing the vulnerability of this patient population to infectious morbidity. These infections likely occurred as a consequence of the underlying leukemia, as well as myelosuppression and cellular immune dysfunction both from prior fludarabine therapy, as well as the subsequent treatment with cladribine. [22] [23] [24] Serious cellular immune dysfunction is suggested by the frequency of opportunistic infections including herpes simplex (localized and disseminated), varicella zoster, central nervous system Toxoplasmosis, and esophageal candidiasis. The use of this therapy clearly mandates close observation for infectious morbidity.
How do we interpret the results of this cladribine trial demonstrating modest activity but significant toxicity? A variety of other agents including the anti-CD20 antibody rituximab and the anti-CD52 antibody Campath-1H have demonstrated activity in fludarabine-refractory CLL even for patients with high risk Rai stage disease. [25] [26] [27] [28] Other agents such as Hu1D10, depsipeptide, PS341, and G3139 are currently under evaluation in clinical trials. [29] [30] [31] Discrimination between the benefit of these new agents and other standard alternative cytotoxic therapies, such as cladribine, is of great importance. Application of any agent, including cladribine as administered in this trial would be of significant clinical interest if prolonged responses were attainable in patients who had unfavorable prognostic factors such as p53 mutations, 32, 33 cytogenetic abnormalities including deletion of 11q and 17p, [34] [35] [36] unmutated VH genes, 37, 38 CD38 expression, 38, 39 and overexpression of anti-apoptotic proteins such as mcl-1. 40 Unfortunately, pre-treatment samples from patients treated in this trial are not available to allow assessment of these variables between responding and non-responding patients. However, future trials attempting to reproduce these data or with other novel therapies should be tested for their ability to abrogate drug resistance associated with each of these factors. Given both the clinical data presented herein and the recent laboratory results substantiating the findings that the purine analogs fludarabine and cladribine may induce apoptosis through a different pathway, 21 consideration of examining cladribine combinations in patients with less prior treatment or at lower doses than used in this trial may be warranted.
